Literature DB >> 25181978

[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures].

U Kiltz1, J Sieper, H Kellner, D Krause, M Rudwaleit, J-F Chenot, A Stallmach, S Jaresch, J Braun.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25181978     DOI： 10.1007/s00393-014-1443-7

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  126 in total

1.  An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover.

Authors:  A P Cairns; S A Wright; A J Taggart; S M Coward; G D Wright
Journal:  Ann Rheum Dis       Date:  2004-04-19       Impact factor: 19.103

2.  Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.

Authors:  Jean David Cohen; Irina Bournerias; Valérie Buffard; Agnès Paufler; Xavier Chevalier; Martine Bagot; Pascal Claudepierre
Journal:  J Rheumatol       Date:  2006-10-01       Impact factor: 4.666

3.  Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study.

Authors:  Walter P Maksymowych; David Salonen; Robert D Inman; Proton Rahman; Robert G W Lambert
Journal:  J Rheumatol       Date:  2010-05-01       Impact factor: 4.666

4.  High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study).

Authors:  Federico Navarro-Sarabia; José L Fernández-Sueiro; Juan C Torre-Alonso; Jordi Gratacos; Rubén Queiro; Carlos Gonzalez; Eduardo Loza; Luis Linares; Pedro Zarco; Xavier Juanola; José Román-Ivorra; Emilio Martín-Mola; Raimon Sanmartí; Juan Mulero; Gema Diaz; Yolanda Armendáriz; Eduardo Collantes
Journal:  Rheumatology (Oxford)       Date:  2011-06-23       Impact factor: 7.580

5.  The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis.

Authors:  S Arends; H R Lebbink; A Spoorenberg; L B Bungener; C Roozendaal; E van der Veer; P M Houtman; E N Griep; P C Limburg; C G M Kallenberg; G J Wolbink; E Brouwer
Journal:  Clin Exp Rheumatol       Date:  2010-10-22       Impact factor: 4.473

6.  Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register.

Authors:  Suzanne M M Verstappen; Yvonne King; Kath D Watson; Deborah P M Symmons; Kimme L Hyrich
Journal:  Ann Rheum Dis       Date:  2011-02-28       Impact factor: 19.103

7.  Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis.

Authors:  Walter P Maksymowych; Katherine L Gooch; Robert L Wong; Hartmut Kupper; Désirée van der Heijde
Journal:  J Rheumatol       Date:  2009-12-01       Impact factor: 4.666

8.  A new strategy of drug treatment in NSAID-unresponsive ankylosing spondylitis: combination of pamidronate and methylprednisolone monthly intravenous infusions on the background of a combination of disease modifying drugs sulfasalazine and methotrexate.

Authors:  A N Malaviya; S Kapoor; S Garg; I Ahmad; R R Raja
Journal:  J Assoc Physicians India       Date:  2007-03

9.  Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study.

Authors:  Jürgen Braun; Atul Deodhar; Robert D Inman; Désirée van der Heijde; Michael Mack; Stephen Xu; Benjamin Hsu
Journal:  Ann Rheum Dis       Date:  2011-10-19       Impact factor: 19.103

10.  Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.

Authors:  S Visvanathan; C Wagner; J C Marini; D Baker; T Gathany; J Han; D van der Heijde; J Braun
Journal:  Ann Rheum Dis       Date:  2007-07-20       Impact factor: 19.103
View more
  5 in total

Review 1.  [Evidence-based recommendations on diagnostics and therapy of axial spondyloarthritis : S3 guidelines of the German Society of Rheumatology (DGRh) in cooperation with the Association of the Scientific Medical Societies in Germany (AWMF)].

Authors:  U Kiltz; M Rudwaleit; J Sieper; J Braun
Journal:  Z Rheumatol       Date:  2017-03       Impact factor: 1.372

Review 2.  [Biologics and further new drugs for rheumatic diseases since 2000].

Authors:  K Krüger
Journal:  Orthopade       Date:  2018-11       Impact factor: 1.087

Review 3.  [Management of axial spondyloarthritis].

Authors:  U Kiltz; X Baraliakos; J Braun
Journal:  Internist (Berl)       Date:  2016-11       Impact factor: 0.743

4.  Spine Fractures in Ankylosing Diseases: Recommendations of the Spine Section of the German Society for Orthopaedics and Trauma (DGOU).

Authors:  Maximilian Reinhold; Christian Knop; Christian Kneitz; Alexander Disch
Journal:  Global Spine J       Date:  2018-09-07

5.  Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates.

Authors:  Stephanie Harvard; Daphne Guh; Nick Bansback; Pascal Richette; Alain Saraux; Bruno Fautrel; Aslam Anis
Journal:  Cost Eff Resour Alloc       Date:  2017-09-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.